3D MOLECULAR DOCKING COMBINED WITH AI-DRIVEN VIRTUAL SCREENING TO REPURPOSE FDA-APPROVED DRUGS FOR RARE NEURODEGENERATIVE DISEASES. International Journal of Experimental Biology, [S. l.], v. 2, n. 01, p. 50–73, 2024. Disponível em: https://ijeb.online/index.php/IJEB/article/view/23. Acesso em: 30 apr. 2026.